Pritchard J F, Schneck D W, Hayes A H
Res Commun Chem Pathol Pharmacol. 1980 Feb;27(2):211-22.
Repetitive oral propranolol administration to rats (100 mg/kg/day for 5 days) resulted in an 80% inhibition of propranolol Type I spectral binding capacity. This paralleled a similar reduction in the microsomal metabolism of propranolol when incubated at low substrate concentrations (less than 2 microM). Propranolo was converted both in vitro and in vivo by a microsomal mixed function oxidase to a reactive intermediate metabolite capable of covalently binding with microsomal macromolecules. We propose that covalent binding of the intermediate to the catalytic site of a form(s) of cytochrome P-450 that metabolizes propranolol would account for the marked inhibition of propranolol metabolism observed following propranolol pretreatment.
对大鼠重复口服普萘洛尔(100毫克/千克/天,持续5天)导致普萘洛尔I型光谱结合能力受到80%的抑制。这与在低底物浓度(小于2微摩尔)下孵育时普萘洛尔微粒体代谢的类似降低情况相平行。普萘洛尔在体外和体内均被微粒体混合功能氧化酶转化为一种能够与微粒体大分子共价结合的活性中间代谢产物。我们提出,该中间产物与代谢普萘洛尔的细胞色素P - 450某种形式的催化位点的共价结合,将解释普萘洛尔预处理后观察到的普萘洛尔代谢的显著抑制现象。